financetom
Business
financetom
/
Business
/
US renewable fuel credits rally to multi-month highs despite Trump reelection
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US renewable fuel credits rally to multi-month highs despite Trump reelection
Nov 9, 2024 1:35 PM

NEW YORK (Reuters) - U.S. renewable fuel credits rose to multi-month highs on Friday on increased demand from refiners trying to comply with mandates and higher prices for soyoil, surprising traders who expected Donald Trump's reelection as U.S. president to weigh on the market.

Rising prices for the credits, also called Renewable Identification Numbers (RINs), are welcome news for biofuel producers who depend on them to make up for high output costs. However, they also worsen the pain for petroleum refiners whose profit margins have slumped sharply this year due to oversupply and weak demand.

Prices for both the D4 RINs, issued to biomass-based diesel producers, and the D6 RINs, issued to ethanol suppliers, rose as high as 79 cents each on Friday, traders said.

Those are the highest levels since January, according to LSEG data.

The U.S. government mandates mixing of low-carbon fuels in the country's transportation fuel mix, and issues RINs to companies supplying them. Refiners who do not meet their targets can buy RINs from others or risk fines.

Trump's victory in this week's U.S. elections had led to speculation that small refineries will find it easier to get exemptions to their RIN generation targets under his administration, OPIS analyst Tom Kloza said.

However, Trump has not yet outlined any plans to do that.

"There's uncertainty around whether Trump will reintroduce widespread small refinery exemptions, so some small refiners may be buying now to avoid being caught short," said Alex Hodes, analyst at energy brokerage StoneX.

Market participants also expect fewer RINs to be available for trade next year, partly due to tighter government mandates and weak fuel demand reducing renewables blending, said Will Faulkner, founder of industry analysis firm Carbon Acumen.

Meanwhile, soybean oil prices have also rallied this week on expectations that Trump could impose tariffs on imports of biofuel feedstocks.

Higher prices for feedstocks erode producer margins, making them price their RINs higher, said Paul Niznik, director of energy at consultancy firm Capstone.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Mattr Prices $129.3 Million Offering of Debt Subscription Receipts
Mattr Prices $129.3 Million Offering of Debt Subscription Receipts
Dec 6, 2024
09:05 AM EST, 12/06/2024 (MT Newswires) -- Mattr ( MTTRF ) on Friday priced an offering of 125,000 debt subscription receipts at $1,034 each, including accrued but unpaid interest, for $129.3 million in proceeds. The company plans to use the proceeds to pay a portion of the purchase price for its previously announced indirect acquisition of AmerCable, which is expected...
Sector Update: Consumer Stocks Advance Pre-Bell Friday
Sector Update: Consumer Stocks Advance Pre-Bell Friday
Dec 6, 2024
09:05 AM EST, 12/06/2024 (MT Newswires) -- Consumer stocks were advancing pre-bell Friday as the Consumer Staples Select Sector SPDR Fund ( XLP ) was up 0.1% and the Consumer Discretionary Select Sector SPDR Fund ( XLY ) was 0.8% higher recently. Lululemon athletica (LULU) shares were over 8% higher after the company reported a surge in fiscal Q3 earnings...
After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer
After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer
Dec 6, 2024
On Friday, the FDA accepted and granted Priority Review AstraZeneca Plc's ( AZN ) supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) for patients with muscle-invasive bladder cancer (MIBC). The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is anticipated during the second quarter of 2025. The supplement application is based on data from the NIAGARA...
Ubisoft shareholders in talks over possible buyout terms, sources say
Ubisoft shareholders in talks over possible buyout terms, sources say
Dec 6, 2024
* Guillemot family seen wanting to retain control in buyout * Tencent ( TCTZF ) undecided on increasing stake * Minority shareholders push for sale amid stock decline By Amy-Jo Crowley and Julie Zhu LONDON/HONG KONG, Dec 6 (Reuters) - Shareholders of Ubisoft Entertainment SA are considering how to structure a possible buyout of the Assassin's Creed video game maker...
Copyright 2023-2025 - www.financetom.com All Rights Reserved